Endocuff Vision for assisting visualisation during colonoscopy

Resource impact statement

No resource impact is anticipated

The guidance states Endocuff Vision should be considered as an option for people having a colonoscopy as part of bowel cancer screening. There is limited evidence for the benefits of Endocuff Vision in a non-screening population.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact from using Endocuff Vision will be less than £1 million per year in England (or £1,800 per 100,000 population).

The guidance indicates the use of Endocuff Vision will lead to savings. The savings are calculated to average £53 per person using Endocuff over a 10-year time period for a colonoscopist with a baseline adenoma detection rate of 51%. Savings are calculated from an increase in removal of adenomas resulting in a reduced risk of people contracting bowel cancer and requiring treatment. Overall savings are not expected to be significant at a national level.

This unit cost of the Endocuff Vision is around £12.

In 2018/19 this technology was commissioned by NHS England through the Innovation and Technology Payment. The technologies that will be funded during 2019/20 have not yet been announced. The bowel screening programme is commissioned by public health commissioners. Providers are NHS hospital trusts.